Lifewatch Services Inc v. Highmark Inc (2018)

Inc. v. Highmark Inc., 902 F.3d 323, 331 (3d Cir. 2018).

Inc. v. Highmark, Inc., 902 F.3d 323, 340 (3d Cir. 2018) (seller of telemetry monitor adequately alleged anticompetitive effects, in part, by showing that alleged conspiracy to deny insurance coverage for telemetry monitors reduced demand for more effective devices and reduced the quality of cardiac monitors in general).

Inc. v. Highmark Inc., 902 F.3d 323, 341 (3d Cir. 2018) (addressing antitrust standing after addressing the pled antitrust violation).

Inc. v. Highmark Inc., 902 F.3d 323, 338 (3d Cir. 2018) (noting that plaintiff “forfeited . . . theories by not fully briefing them on appeal”); Barna v. Bd. of Sch.

Inc., 902 F.3d at 337 (“A plaintiff bears the burden of defining both a relevant geographic and a relevant product market.”).

Inc. v. Highmark Inc., 902 F.3d 323, 333 (3d Cir. 2018) (quoting In re Ins.

Inc. v. Highmark Inc., 902 F.3d 323, 343 (3d Cir. 2018).

Inc. v. Highmark Inc., 902 F.3d 323, 333 (3d Cir. 2018).

Inc. v. Highmark Inc., 902 F.3d 323, 337 (3d Cir. 2018); see also Todd v. Exxon Corp., 275 F.3d 191 , 199-200 (2d Cir. 2001) (“Because market definition is a deeply fact-intensive inquiry, courts hesitate to grant motions to dismiss for failure to plead a relevant product market.”) Moving on to FMC’s argument that Rightline failed to allege any degree of foreclosure of the market so as to harm competition, I note that “there is no fixed percentage at which foreclosure become…

Inc. v. Highmark Inc., 902 F.3d 323, 342 (3d Cir. 2018) (finding a causal link in spite of intervening factors “such as [the health plan’s] independent ability to decline coverage of telemetry monitors, a doctor’s choice not to prescribe telemetry monitors, and a patient’s desire for alternative treatments”); In re Warfarin Sodium Antitrust Litig., 214 F.3d 395, 401 (3d Cir. 2000) (concluding plaintiff had antitrust standing even with “various links of middlemen”); but see A…

Inc. v. Highmark Inc., 902 F.3d 323, 342 (3d Cir. 2018) (finding a causal link in spite of intervening factors “such as [the health plan’s] independent ability to decline coverage of telemetry monitors, a doctor’s choice not to prescribe telemetry monitors, and a patient’s desire for alternative treatments”); In re Warfarin Sodium Antitrust Litig., 214 F.3d 395, 401 (3d Cir. 2000) (concluding plaintiff had antitrust standing even with “various links of middlemen”); but see A…

Inc. v. Highmark Inc., 902 F.3d 323, 332 (3d Cir. 2018).

Inc. v. Highmark Inc., 902 F.3d 323, 337 (3d Cir. 2018); see also Todd v. Exxon Corp., 275 F.3d 191, 199-200 (2d Cir. 2001) (“Because market definition is a deeply fact- intensive inquiry, courts hesitate to grant motions to dismiss for failure to plead a relevant product market.”).

Inc. v. Highmark, Inc., 902 F.3d 323, 333 (3d Cir. 2018) (quoting In re Ins.

Although there is no finite set of plus factors and no exhaustive list exists, the Third Circuit has explained: For circumstantial evidence of an agreement, then, a plaintiff must allege both parallel conduct and something “more,” which we have sometimes called a “plus factor.” This “more” could include evidence (1) “that the defendant had a motive to enter into a . . . conspiracy,” (2) “that the defendant acted contrary to its interests,” or (3) “implying a traditional cons…

Inc. v. Highmark Inc., 902 F.3d 323, 331 (3d Cir. 2018).

Inc. v. Highmark Inc., 902 F.3d 323, 331 (3d Cir. 2018).

Inc. v. Highmark Inc., 902 F.3d 323, 337 (3d Cir. 2018) (“[A]bsent [] obvious oversights, courts are cautious before dismissing [a complaint] for failure to define a relevant market.”).

LifeWatch Servs. v. Highmark Inc., 902 F.3d 323, 335 (3d Cir. 2018).

E.g., Indiana Fed’n of Dentists, 476 U.S. at 450–451, 459 11 (horizontal agreement between competing dentists not to share X rays with insurance companies); 12 Lifewatch Servs., 902 F.3d at 335 (horizontal restraint amongst competitors); Eastman Kodak Co., 13 125 F.3d at 1201 (the plaintiffs withdrew their tying claims and only litigated § 2 claims).

Inc. v. Highmark Inc., 902 F.3d 323, 336 (3d Cir. 2018) (quoting Ohio v. Am.

Sherman Act To prevail on claims arising under 15 U.S.C. §1 , a plaintiff must allege (1) an agreement (2) to restrain trade unreasonably.” Lifewatch Serv., Inc. v. Highmark, Inc. 902 F.3d 323, 331-32 (3d Cir. 2018).

Inc. v. Highmark Inc. , 902 F.3d 323, 333 (3d Cir. 2018)...

Under the Sherman Act, a restraint of trade claim consists of a concerted action imposing an unreasonable restraint on trade that “inhibits competition in the relevant market.” Lifewatch Services, Inc. v. Highmark Inc., 902 F.3d 323, 332-35 (3d Cir. 2018).

The Supreme Court has “articulated several factors to consider when analyzing whether a plaintiff has such standing.” LifeWatch Servs. v. Highmark Inc., 902 F.3d 323, 341 (3d Cir. 2018) (citing AGC, 459 U.S. at 538 ).

The Supreme Court has “articulated several factors to consider when analyzing whether a plaintiff has such standing.” LifeWatch Servs. v. Highmark Inc., 902 F.3d 323, 341 (3d Cir. 2018) (citing AGC, 459 U.S. at 538 ).

See Lifewatch Servs. , 902 F.3d at 334-35 (holding defendant insurers' identical refusal to reimburse a product that "many sophisticated third parties," including physicians and state medical review boards, agreed was medically necessary was a plus factor); Evergreen Partnering Grp., Inc. v. Pactiv Corp. , 720 F.3d 33 , 49-51 (1st Cir. 2013) (finding a plus factor where defendants acted against their independent interests by uniformly refusing to adopt a policy "standard in …